By Reuters
February 23, 2026 – 6:02 AM PST
(Reuters) – Eli Lilly (LLY.N) said on Monday it received the U.S. Food and Drug Administration’s approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a single device.
